Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Feb 15, 2012 (Vol. 32, No. 4)

Coupling SPR Increases Value

  • Click Image To Enlarge +
    Technician using a surface plasmon resonance machine to study biomolecular interactions. SPR involves the excitation of surface plasmons by light. A typical use for this technology is the characterization of antibodies. [Andrew Brookes, National Physical Laboratory/Photo Researchers]

    Surface plasmon resonance (SPR) is not the new kid on the block. It’s been an industry workhorse technology for more than 20 years. What is new is coupling this premier technology with thermodynamic methodologies or molecular dynamics simulations. When used together, these provide a powerful means to generate a greater depth of information than either can alone. Further, the ability to sensitively gauge kinetics and equilibrium information positions use of SPR as an adjunct to high-throughput screening and affinity ranking during lead optimization.

    The recent “Developments in Protein Interaction Analysis” conference hosted by GE Healthcare highlighted several of these synergistic partnerships as well as new ways SPR is being employed in the modern-day drug discovery arena.

    Typical SPR requires very little material and does not need an external probe for monitoring interactions. This label-free, real-time technology is initiated by immobilizing a component, such as protein or nucleic acid, onto a sensor chip. The other component(s) are then injected over the flow cell(s) in the desired buffer. SPR detection relies on a resonance interaction between the light beam and the thin metal film on the sensor chip.

    Allostery is the scientifically intriguing process in which the binding of a ligand to a macromolecule alters ligand binding at distant sites. Named by Nobelist Jacques Monod in the early 1960s to describe the sigmoidal binding curve of oxygen to hemoglobin, its molecular mechanisms have been a holy grail of biochemistry ever since.

    “Scientists have spent decades trying to understand protein allostery through ligand-binding kinetics, thermodynamics, and structures, but we still do not have a unified picture,” said Jannette Carey, Ph.D., professor of chemistry, Princeton University. Besides its academic interest, allostery is thought by some to offer a new approach to drug discovery.

    Dr. Carey’s laboratory uses a combination of experimental and computational techniques to study allostery in several protein-ligand systems.

    “We initially quantify a binding process using biochemical and biophysical approaches, including isothermal titration calorimetry (ITC) and SPR. ITC measures the heat flow associated with a molecular interaction, complementing SPR by providing thermodynamic information.

    “Recently we added molecular dynamics simulations (MD) to our arsenal, in collaboration with Professor Rüdiger Ettrich of the Czech Academy of Sciences. MD applies Newton’s laws of motion to molecules, providing a temporal description of structural changes.

    “I was stunned when we saw that MD was able to trace an allosteric response from specific atomic detail to global conformational change.”

    Experimentalists, including Dr. Carey, initially were skeptical of MD. “MD can be used to make experimentally testable predictions, putting it firmly in the realm of the scientific method. Besides requiring huge computational power, MD interpretation is complex and subtle, and thus a job for experts. So don’t expect an app for that any time soon.”

    Dr. Carey’s take-home message is that “quantitative studies of ligand binding are the first step in understanding allostery and the biological roles of molecular interactions. In every course I teach I try to work ligand-binding theory and practice into the curriculum.”

  • DNA Therapeutics

    With the identification and sequencing of most of the human genome in hand (and some disease-causing microorganisms), new opportunities to devise DNA-specific therapeutics are rapidly evolving.

    “Gene-specific therapeutics require developing highly specific DNA-targeting molecules that recognize binding sites that are 10–15 bases long,” said W. David Wilson, Ph.D., professor of biophysical chemistry, department of chemistry, Georgia State University.

    “Most of these are designed to target the minor groove DNA. The minor groove of DNA, as opposed to the larger major groove, is a better drug target since small molecules can more easily span this region.”

    Dr. Wilson is utilizing SPR and microcalorimetry methods to design and evaluate compounds. “Our goals are to understand the details of DNA molecular recognition. DNA does nothing unless it interacts with another molecule. Designing small molecules that target the minor groove has the potential to shut down entire genes of pathogens, such as malaria.”

    Dr. Wilson and colleagues designed both symmetric compounds (with two linked amidine-benzimidazole-phenyl units to specifically target AT sequences) and linked hairpin type heterocyclic compounds.

    “Both types have the potential for enhanced binding specificity by recognizing both strands of duplex DNA. We use biosensor-SPR and microcalorimetry to evaluate the interaction of compounds with different DNA sequences.”

    Coupling SPR and microcalorimetry provides even more information about compounds. “Microcalorimetry offers a means for much more detail relating to the affinity, and the mechanism of the reaction, such as its entropy and how that drives the reaction. It also provides information as to how chemical variations might contribute.”

    An advantage of SPR is that it allows monitoring binding reactions in real time. “We use a gold-plated chip that can be functionalized with carboxymethyl dextran. We link streptavidin to that and couple biotin to the DNA. The binding of DNA to the chip will produce a signal change over a range of compound concentrations, allowing us to determine standard kinetics and equilibrium constants.”

    Dr. Wilson found some surprises. “We studied such issues as the levels of DNA binding affinity that can be obtained with our relatively simple compound set, how compounds folded after binding, and the differences between compounds that bind to two sites versus one, etc.

    “We are excited by our findings. We saw that a compound can do one of three things. First, it can fold back on itself while in the minor groove, and second, two compounds can—as expected—bind to different sites.

    “But to our surprise, a third finding was that two compounds can form stacked dimers in the groove. We still don’t completely understand all of the dynamics, and will need high-powered binding methods to sort this out. But we believe this is something we can accomplish. Ultimately we then will pursue animal studies.”

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »